Swedish diabetes company raises USD 17.5m for phase III trial

Among other things, the need for extra funding for a phase III study with Diamyd Medical's diabetes vaccine candidate has made the Swedish company carry out a directed share issue.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app